Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials.

Smith, Saxon D; Stratigos, Alexandros; Augustin, Matthias; Carrascosa, Jose Manuel; Grond, Susanne; Riedl, Elisabeth; Xu, Wen; Patel, Himanshu; Lebwohl, Mark

Smith, Saxon D; Stratigos, Alexandros; Augustin, Matthias; Carrascosa, Jose Manuel; Grond, Susanne; Riedl, Elisabeth; Xu, Wen; Patel, Himanshu; Lebwohl, Mark.

Afiliación

Smith SD; ANU Medical School, ANU College of Health and Medicine, The Australian National University, Canberra, Australian Capital Territory, Australia. dr.saxon.smith@gmail.com.
Stratigos A; Department of Dermatology, University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece.
Augustin M; Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Carrascosa JM; Department of Dermatology, Hospital Universitari Germans Trias I Pujol, Badalona, Universidad Autónoma de Barcelona, IGTP, Badalona, Spain.
Grond S; Eli Lilly and Company, Indianapolis, IN, USA.
Riedl E; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Xu W; Eli Lilly and Company, Indianapolis, IN, USA.
Patel H; Eli Lilly and Company, Indianapolis, IN, USA.
Lebwohl M; Department of Dermatology, Mount Sinai Hospital, New York, NY, USA.

Dermatol Ther (Heidelb) ; 13(8): 1773-1787, 2023 Aug.

Article en En | MEDLINE | ID: mdl-37351831

Palabras clave

Ixekizumab; Long-term; Malignancy; Melanoma; Non-melanoma skin cancer; Psoriasis; Safety; Skin cancer; Skin neoplasm

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2023 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google